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Background
HIV virions incorporate HLA class I and II molecules dur-
ing budding from the host cell, and these proteins are
potential alternative targets for neutralising antibodies.
Exposure to foreign HLA may result in a protective
immune response. Immunisation of macaques with inac-
tivated SIV grown in human cells has been shown to
induce protection against challenge with virus grown in
human cells. We have used novel recombinant HLA-I and
-II dextran-attached antigens to find out if immunisation
of macaques can elicit protection against a high dose i.v.
SHIV challenge.
Methods
Groups of eight female rhesus macaques were immunised
with HLA class I (A*01, A*02, A*03 and A*11) and II
(DRB1*04) (group 1), these antigens plus trimeric HIV-
1gp140 and SIVp27 (group 2), HIV-1gp140 and SIVp27
(group 3), all with Hsp70 coupled to dextran backbones,
and mixed with the Titermax Gold adjuvant. Group 5
received the same vaccine as group 2, but without Titer-
max Gold. Four weeks after the last immunisation these
macaques plus eight naive macaques were challenged i.v.
with 18 MID50 of SHIV-SF162P4 grown in the human T
cell line C8166-CCR5 (expressing HLA-A*01 and -
DRB1*04).
Results
Group 2 animals, two of which remained uninfected,
showed a significantly decreased viral load (p < 0.05)
compared to the naïve animals. Group 1 showed some
delay in the viremia. No protection was observed in
groups 3 and 5. Complement-dependent neutralising
antibodies as well as anti-HLA and anti-C8166 antibodies
were elicited in groups 1 and 2, with titers being inversely
correlated with the plasma viral load at 2 weeks postinfec-
tion and highest in the two protected animals.
Conclusion
Significant protection against a high-dose i.v. SHIV-
SF162P heterologous challenge in macaques has been
achieved by immunisation with recombinant HLA class I
and II in combination with trimeric HIVgp140 and
SIVp27 antigens. The protection correlated with induction
of anti-HLA antibodies and complement-dependent neu-
tralising antibodies.
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